Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07154901 | Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373) | PHASE1 | ACTIVE NOT_RECRUITING | 34 | — | — | Aug 18, 2025 | Jun 15, 2026 | May 22, 2026 | 2 | United States |
Area under the concentration-time curve from zero to infinity
Area under the concentration-time curve from zero to the last measurable concentration
Maximum observed plasma concentration
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Healthy participants will receive a single subcutaneous injection of AZD2373. |
| Group 2 | EXPERIMENTAL | Severe renal impairment participants will receive a single subcutaneous injection of AZD2373. |
| Group 3 | EXPERIMENTAL | Moderate renal impairment participants will receive a single subcutaneous injection of AZD2373 |
| Group 4 | EXPERIMENTAL | Mild renal impairment participants will receive a single subcutaneous injection of AZD2373 |
| Name | Type | Description |
|---|---|---|
| Opemalirsen (AZD2373) | DRUG | Single, subcutaneous injection of AZD2373 |
Inclusion Criteria: * Participants are eligible to be included in the study only if all of the following criteria apply: Age 1. Participant must be 18 to 80 years of age, inclusive, at the time of signing the informed consent. Type of Participant and Disease Characteristics For all participants, ...